📬 Melanoma Intelligence Digest — Week 2026-W36

Merck/Moderna's Phase 3 INTerpath-001 topline (N=1,137) of intismeran autogene plus pembrolizumab in resected stage IIB-IV melanoma dominated the week, alongside a JITC correlative analysis of TILT-123 plus IL-2-free TIL therapy, continued debate over the RP1/nivolumab approval, and BioNTech's futility stop in colorectal mRNA vaccine.

⚡ TL;DR

🐦 Twitter / 🦋 Bluesky

Update: INTerpath-001 topline lands as the first positive Phase 3 of an individualized mRNA neoantigen therapy, and the conversation turns to magnitude, durability and OS — Phase 3 INTerpath-001 met its primary recurrence-free survival and key secondary distant metastasis-free survival endpoints with statistically significant and clinically meaningful improvements versus pembrolizumab alone in completely resected stage IIB-IV melanoma
BioNTech's colorectal mRNA vaccine futility stop is used to bound the INTerpath-001 result to the population studied — BioNTech is stopping its colorectal cancer trial for futility while other mRNA cancer vaccine programs continue

Full details below ↓

📄 What's Being Published

Manuscripts:

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy. — Haybout Lyna et al., J Immunother Cancer

17 patients with checkpoint-inhibitor-resistant metastatic melanoma received up to six intratumoral TILT-123 injections followed by TIL infusion, without lymphodepleting chemotherapy or IL-2 post-conditioning. Tumor biopsy analyses revealed early innate immune activation marked by natural killer-cell expansion and cytotoxic gene upregulation, followed by increased intratumoral T-cell infiltration; enrichment of CD27+CD28+ memory-precursor CD8+ T cells was associated with favorable clinical outcomes, while elevated monocytic myeloid-derived suppressor cells and angiogenic/inflammatory cytokines after combination treatment were associated with disease progression. Correlative analysis in pooled TILT-123 cohorts identified serum epidermal growth factor as a candidate biomarker for stratifying and monitoring patients.

Clinical bottom line: With survival follow-up extended to March 2026, the TUNINTIL correlative analysis pins outcomes of this chemotherapy- and IL-2-free TIL approach to CD27+CD28+ memory-precursor CD8+ T cells and to myeloid suppressor/cytokine burden, and nominates serum EGF as a stratification biomarker for the next round of trials.

Read full article →

🗂 Every paper considered this week, including the ones that didn’t make it →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

Update: INTerpath-001 topline lands as the first positive Phase 3 of an individualized mRNA neoantigen therapy, and the conversation turns to magnitude, durability and OS

Phase 3 INTerpath-001 (N=1,137) met its primary recurrence-free survival and key secondary distant metastasis-free survival endpoints, demonstrating statistically significant and clinically meaningful improvements compared with pembrolizumab alone in completely resected stage IIB–IV melanoma — marking what clinicians described as the first positive Phase 3 trial of an individualized neoantigen therapy and of an mRNA-based cancer therapy. Intismeran autogene, in which up to 34 patient-specific neoantigens can be selected, was framed by Moderna as the first and only combination regimen to demonstrate a clinically meaningful improvement over pembrolizumab alone, a current standard of care, and by Melanoma Institute Australia's principal investigator as the first Phase 3 study to show intismeran plus pembrolizumab can reduce the risk of recurrence or death versus pembrolizumab alone, with full results to be presented at a congress later this year. Commentators simultaneously described the readout as a landmark moment in melanoma, cancer immunology, and IO drug development, characterized it as derisking cancer vaccines in Phase 3 melanoma, and noted it as the first large randomized controlled trial of a cancer treatment vaccine. With only topline RFS and DMFS announced, clinicians outside melanoma immediately asked whether adjuvant personalized vaccine trials fully accrued or ongoing in lung — and other solid tumors — can reproduce the result, while the central debate remains how adjuvant melanoma practice should respond before magnitude of benefit, durability, and overall survival are known.

Discussed by: @EladSharonMD, @OncoAlert, @OncoAlert, @EladSharonMD, @EladSharonMD, @EladSharonMD, @DrJNaidoo, @EladSharonMD, @OncoAlert, @MelanomaAus, @AnaArance1, @Latinamd, @EladSharonMD, @EladSharonMD, @EladSharonMD, @DrMirallas, @Dr_ElvinaA, @ASCOPost

→ View representative tweet

BioNTech's colorectal mRNA vaccine futility stop is used to bound the INTerpath-001 result to the population studied

BioNTech's decision to stop its colorectal cancer trial for futility, occurring alongside Moderna's positive INTerpath-001 melanoma readout, prompted clinicians to articulate a basic principle: evidence belongs to the population studied, with different cancer, setting, patients, and result separating the two programs. One commentator who had described personalized cancer vaccines as having crossed a major line with positive Phase 3 INTerpath-001 in resected melanoma also noted participation in the adjuvant RCC trial and anticipation of its results, while melanoma specialists argued that much can be built on the mRNA platform to improve the outcomes of patients with cancer. The central question is whether BioNTech's colorectal futility stop should temper cross-tumor extrapolation from the melanoma neoantigen readout, or whether tumor immunogenicity is the deciding variable.

Discussed by: @OncoAlert, @EladSharonMD, @EladSharonMD

→ View representative tweet

🔥 Top Ranked Tweets

Oriol Mirallas MD @DrMirallas

⚡ Great news for #melanoma patients
💉 Combined with Pembro
👇🏽👇🏽
[Quoting @OncoAlert: NEWS FROM INDUSTRY: INTerpath-001 Update in #Melanoma
Source: Merck

Merck and Moderna announced positive Phase 3 results from INTerpath-001, evaluating intismeran autogene, an individualized mRNA-based neoantigen therapy, combined with pembrolizumab 🧪 in patients with completely resected stage IIB-IV melanoma.
✅️ The trial met its primary recurrence-free survival and key secondary distant metastasis-free survival endpoints, demonstrating statistically significant and clinically meaningful improvements compared with pembrolizumab alone.

https://t.co/TW1Y1R2RN5

Pinging our faculty 👇
@GlopesMd
@bmassutis
@UmbertoMalapel1
@christine_lovly
@DrSanjayPopat
@matteolambe
@raalbany
@hoperugo
@stolaney1
@LoiSher
@montypal
@apolo_andrea
@PGrivasMDPhD
@TiansterZhang
@amerseburger
@drenriquegrande
@scserendipity1
@tompowles1
@nataliagandur
@cdanicas
@pashtoonkasi
@CathyEngMD
@BenWestphalen
@CharlesSwanton
@VivekSubbiah
@HaanenJohn

Pinging the OncoAlert AF 🚨
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@nataliagandur]

🔖 0 ❤️ 2 🔁 0 👁 194